Resource centre

Developing Palatable Pediatric Formulations. This webinar explores how you can leverage taste masking, modelling & simulation, clinical PK and taste assessment studies to achieve program success.

This webinar highlights how a fully integrated program can speed up transition from candidate selection to proof of concept and shorten the pathway to clinical development.

This webinar from Quotient Sciences will explore the existing challenges of managing the manufacture and distribution of clinical trial supplies to numerous sites, in multiple countries, and discuss how to streamline your clinical trial supply chain and accelerate your proof-of-concept timeline.

This webinar highlights how a fully integrated development plan can bring together the needs of the drug product team and the clinical development team.

This webinar discusses drug substance manufacturing in early development and the very concept of being fast, agile and innovative.

This presentation uses expert insight and case studies to explore formulation and solubility challenges and discuss the best strategies and technologies for advancing poorly soluble molecules, to deliver success.

This edition of OBN’s Digital Event series is being organized in collaboration with Quotient Sciences and will highlight how a fully integrated development plan can bring together the needs of the drug product team and the clinical development team.

Oncology drugs dominate today’s industry pipeline with over >5500 molecules in development for 2019 alone. With this number of molecules, the stakes are high, increasing the pressure on pharmaceutical scientists to get medications to patients as quickly as possible. But does the focus on speed mean sacrifices are made elsewhere in the development plan? Drug developers need to be mindful of the challenges that come with oncology drug products in order to accelerate to proof-of-concept and onwards towards a successful commercial launch.

With over 300 million people worldwide living with one or more identified rare diseases, the development of new treatments to address these unmet clinical needs is an area of significant focus in the pharmaceutical industry.

This webinar discusses effective strategies being used by biotech and pharmaceutical companies to overcome biopharmaceutic challenges for small molecules in today’s drug development pipeline; and explores alternative approaches for accelerating your early development plan.

This webinar summarizes the key findings of the recent Tufts CSDD research into Translational Pharmaceutics, the innovative approach to drug development. It demonstrates significant time savings of >12 months and financial gains of >$100 million per drug approved.

Building a robust understanding of your API characteristics matched against your development programme goals, supports the efficient transition of drug products from candidate selection through to proof-of-concept. Starting @ 4pm (BST-UK), 11pm (ET), 8am (PT) and 6pm (BST-UK), 1pm (ET), 10am (PT)